Selection of treatment for patients with early stage non-small cell Lung cancer in a multidisciplinary thoracic oncology program

Stuart M. Berman, Mark Huberman, Armin Ernst, David Feller-Kopman, David H. Roberts, Phillip Boiselle, J. Anthony Parker, Danielle McDonald, Nancy Rumplik, Elena A. Nedea, Simon Ashiku, Sidhu P. Gangadharan, Michael Goldstein, Susan Schumer, Sanjay R. Jain, Darren Brennan, Michael S. Buff, Robert L. Thurer, Malcolm Decamp

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Lung cancer is the leading cause of cancer mortality in men and women. More than 170,000 Americans receive a diagnosis of lung cancer annually and the majority of them die of the disease [1]. There is considerable interest in improving treatment for lung cancer given its high impact on society. More than 80% of patients with lung cancer have non-small cell carcinoma (NSCLC). Surgery is the mainstay of treatment for patients with early stage NSCLC and results in cure of about 60-80% of patients with stage I (T1-2N0) disease [2]-[5].

Original languageEnglish (US)
Title of host publicationTreating Tumors that Move with Respiration
PublisherSpringer Berlin Heidelberg
Pages133-144
Number of pages12
ISBN (Print)9783540698852
DOIs
StatePublished - 2007
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Selection of treatment for patients with early stage non-small cell Lung cancer in a multidisciplinary thoracic oncology program'. Together they form a unique fingerprint.

Cite this